<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347983</url>
  </required_header>
  <id_info>
    <org_study_id>MRA230TW EX</org_study_id>
    <nct_id>NCT01347983</nct_id>
  </id_info>
  <brief_title>Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients</brief_title>
  <official_title>Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharma Taiwan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chugai Pharma Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      24 week open-labeled extension study to continue monitoring the same group of patients in the
      previous MRA230TW phase IIIb trial in order to evaluate the long term efficacy and safety of
      tocilizumab.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with an American College of Rheumatology 70 (ACR70) response</measure>
    <time_frame>at week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ACR50 response</measure>
    <time_frame>at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ACR20 response</measure>
    <time_frame>at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline of Swollen joint count(SJC) and Tender joint count(TJC) respectively</measure>
    <time_frame>at baseline and week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in disease activity using 28-joint modified disease activity score (DAS28)</measure>
    <time_frame>at baseline and week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving DAS28 remission (DAS28 &lt; 2.6)</measure>
    <time_frame>at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event incidence</measure>
    <time_frame>from baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to evaluation visits in vital signs</measure>
    <time_frame>from baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Electrocardiogram. From baseline to evaluation visits</measure>
    <time_frame>from baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline visit to evaluation visits in quantitative hematological exam results.</measure>
    <time_frame>from baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline visit to evaluation visits in quantitative Biochemical exam of blood results.</measure>
    <time_frame>from baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline visit to evaluation visits in quantitative serum lipid exam results.</measure>
    <time_frame>from baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline visit to evaluation visits in quantitative urinalysis results.</measure>
    <time_frame>from baseline to week 24</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">72</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab+Methotrexate(MTX)</intervention_name>
    <description>Tocilizumab: 8 mg/kg every 4 weeks, IV infusion Methotrexate: 10-20 mg/week</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who had completed at least 5 out of the 7 visits scheduled for weeks 2, 4, 8,
             12, 16, 20 and 24 in the tocilizumab Phase IIIb study(MRA230TW).

          -  Patients assigned in the Phase IIIb study(MRA230TW), who had received scheduled dose
             for at least 16 weeks but still failed to achieve adequate treatment response
             characterized by ACR20

        Exclusion Criteria:

          -  Patients who have received a major surgery including joint surgery 8 weeks prior to
             the screening or are scheduled to be operated within 6 months after the enrolment.

          -  Patients with rheumatoid autoimmune disease other than RA, including but not limited
             to SLE(system lupus erythematosus), or significant systemic involvement secondary to
             RA.

          -  Patients who belong to the Class IV of the ACR classification criteria for functional
             status of RA. (ACR Amended Criteria for the Classification of Functional Capacity in
             Rheumatoid Arthritis; Class IV: Largely or wholly incapacitated with patient bedridden
             or confined to wheel chair, permitting little or no self-care).

          -  Patients with a history of hypersensitivity to human, humanized or murine monoclonal
             antibodies or patients with contraindication for them.

          -  Patients who currently have or have a history of recurrence of bacterial,
             viral,fungal, or mycobacterial infections or other infectious diseases;
             tuberculosis(TB),atypical mycobacterial disease, clinically significant granulomatous
             disease on chest radiograph, hepatitis B, hepatitis C, or herpes zoster and etc.
             However, a patient with hand &amp; foot fungal infections can participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoshiaki Someya</last_name>
    <role>Study Chair</role>
    <affiliation>Chugai Pharma Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Buddhist Dalin Tzu Chi General Hospital</name>
      <address>
        <city>Chiayi</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital -Kaohsiung</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cathay General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Linkou</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2011</study_first_submitted>
  <study_first_submitted_qc>May 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2011</study_first_posted>
  <last_update_submitted>April 3, 2013</last_update_submitted>
  <last_update_submitted_qc>April 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

